Kane Biotech receives U.S. patent for technology with potential to prevent dental plaque

By Angela McDaniels

Seattle, Nov. 9 - Kane Biotech Inc. said it has been issued a patent by the U.S. Patent and Trademark Office for its competence-stimulating peptide technology, which may have oral hygiene applications.

Kane Biotech is applying its technology toward the development of cavity and plaque-preventing products, including screening for a agent that would inhibit the peptide's ability to form plaque.

"Kane Biotech is committed to gaining worldwide protection for this technology in all other relevant jurisdictions," said vice president of business development Gord Froehlich in a company press release.

The competence-stimulating peptide regulates many functions of Streptococcus mutans, a bacterial strain present in virtually all humans that creates dental plaque, the company said.

Kane Biotech is a Winnipeg, Manitoba-based biotechnology company that develops products to prevent and disperse bacterial biofilms.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.